Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
September 09 2024 - 8:00AM
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage
biopharmaceutical company developing a novel class of therapeutic
biologics to selectively engage and modulate disease-specific T
cells, today announced the appointment of industry veteran Lucinda
Warren as chief business officer (CBO).
With an extensive background and proven expertise in strategic
transactions, portfolio optimization and alliance management
through her extensive tenure at Johnson & Johnson and Jansen,
Ms. Warren will play a pivotal role in advancing Cue Biopharma’s
core corporate objectives following the company’s recent business
restructuring and autoimmune program prioritization.
“We are pleased to welcome Lucinda to the executive team as her
background and wealth of experience align extremely well with our
corporate development initiatives and objectives,” said Daniel
Passeri, chief executive officer of Cue Biopharma. “We remain
strategically focused upon alignment with third-party partnerships
and collaborations to develop our growing platform of potentially
breakthrough immunotherapies, and Lucinda’s broad professional
expertise and experience will enhance our ability to capitalize on
opportunities in a timely and effective manner. Her appointment
underscores our commitment to maximizing value across our portfolio
and delivering meaningful outcomes for both shareholders and
patients.”
Ms. Warren added, “I am excited to join Cue Biopharma at this
important juncture of its corporate development and, as a key
member, support the team in helping drive successful execution of
our strategic business development and partnering initiatives.”
Ms. Warren has over 30 years of global experience in the
pharmaceutical and biotechnology sectors. Most recently, she served
as vice president of business development for Neuroscience and
Japan Regionally at Johnson & Johnson from 2014 to 2024, where
she was responsible for end-to-end business development, including
licensing, mergers and acquisitions, and alliance management. Her
leadership was instrumental in optimizing resources, fostering
high-performing teams, and cultivating strong relationships with
stakeholders. Lucinda's extensive experience also includes
significant roles at Janssen Cilag Australia and Centocor/Janssen
Biologics, where she led business units and managed global
transitions, consistently delivering value through strategic
transactions. Lucinda holds a Bachelor of Science in Biological
Sciences with a minor in Neurology from the University of Alberta
and is an alumna of the Women in Bio Board Room Ready program. She
currently serves on the boards of International School Services
(ISS) and the Association of Strategic Alliance Professionals
(ASAP), contributing her expertise in finance and governance.
About Cue BiopharmaCue Biopharma, a
clinical-stage biopharmaceutical company, is developing a novel
class of injectable biologics to selectively engage and modulate
disease-specific T cells directly within the patient’s body. The
company’s proprietary platform, Immuno-STAT™ (Selective Targeting
and Alteration of T cells), and biologics are designed to harness
the curative potential of the body’s intrinsic immune system
through the selective modulation of disease-specific T cells
without the adverse effects of broad systemic immune
modulation.
Headquartered in Boston, Massachusetts, we are led by an
experienced management team and independent Board of Directors with
deep expertise in immunology and immuno-oncology as well as the
design and clinical development of protein biologics.
For more information please
visit www.cuebiopharma.com and follow us
on X and LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include, but are not limited to, those
regarding: the company’s belief regarding the potential benefits
and applications of its drug candidates and programs, including the
transformational potential of the company’s Immuno-STAT™ platform
to accomplish its mission of developing breakthrough
immunotherapies to establish a new standard of care in the
treatment of cancer and autoimmune disease; the near-term and
intermediate value creation potential of its autoimmune programs;
the company’s intention to preserve the value of its oncology
programs; the company’s business strategies, plans and prospects,
including those related to the prioritization of CUE-401 and
CUE-501, and the potential benefits of the company’s program
prioritization and realignment on its burn rate; and the cash
runway of the company and the sufficiency of the company’s cash and
cash equivalents to fund its operations. Forward-looking
statements, which are based on certain assumptions and describe the
company’s future plans, strategies and expectations, can generally
be identified by the use of forward-looking terms such as
“believe,” “expect,” “may,” “will,” “should,” “would,” “could,”
“seek,” “intend,” “plan,” “goal,” “project,” “estimate,”
“anticipate,” “strategy,” “future,” “likely,” “promise” or other
comparable terms, although not all forward-looking statements
contain these identifying words. All statements other than
statements of historical facts included in this press release
regarding the company’s strategies, prospects, financial condition,
operations, costs, plans and objectives are forward-looking
statements. Important factors that could cause the company’s actual
results and financial condition to differ materially from those
indicated in the forward-looking statements include, among others,
the company’s ability to shift its focus to its autoimmune assets
and achieve the cost savings that it is projecting; the company’s
limited operating history, limited cash and a history of losses;
the company’s ability to achieve profitability; potential setbacks
in the company’s research and development efforts including
negative or inconclusive results from its preclinical studies or
clinical trials or the company’s ability to replicate in later
clinical trials positive results found in preclinical studies and
early-stage clinical trials of its product candidates; serious and
unexpected drug-related side effects or other safety issues
experienced by participants in clinical trials; its ability to
secure required U.S. Food and Drug Administration (“FDA”)
or other governmental approvals for its product candidates and the
breadth of any approved indication; adverse effects caused by
public health pandemics, including possible effects on the
company’s operations and clinical trials; delays and changes in
regulatory requirements, policy and guidelines including potential
delays in submitting required regulatory applications to the FDA;
the company’s reliance on licensors, collaborators, contract
research organizations, suppliers and other business partners; the
company’s ability to obtain adequate financing to fund its business
operations in the future and ability to continue as a going
concern; the company’s ability to maintain and enforce necessary
patent and other intellectual property protection; competitive
factors; general economic and market conditions and the other risks
and uncertainties described in the Risk Factors and Management's
Discussion and Analysis of Financial Condition and Results of
Operations sections of the company’s most recently filed Annual
Report on Form 10-K and any subsequently filed Quarterly Report(s)
on Form 10-Q. Any forward-looking statement made by the company in
this press release is based only on information currently available
to the company and speaks only as of the date on which it is made.
The company undertakes no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Investor Contact Marie Campinell Senior
Director, Corporate CommunicationsCue Biopharma,
Inc.mcampinell@cuebio.com
Media ContactJonathan PappasLifeSci
Communicationsjpappas@lifescicomms.com
Cue Biopharma (NASDAQ:CUE)
Historical Stock Chart
From Nov 2024 to Dec 2024
Cue Biopharma (NASDAQ:CUE)
Historical Stock Chart
From Dec 2023 to Dec 2024